Perioperative and functional outcomes following Holmium Enucleation of Prostate (HoLEP) in men with massive prostates (≥150cc)
BAUS ePoster online library. Tay L. 06/21/21; 319074; p3-6
Disclosure(s): n/a
Ms. Li June Tay
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Introduction
There is limited evidence on perioperative and functional outcomes in patients with massive prostates undergoing HoLEP. In this study we assess outcomes following HoLEP in men with a prostate volume of ≥150cc and compared this to men with a prostate volume of ≤150cc.
Patients & Methods
We analysed our prospective database of consecutive patients undergoing HoLEP in a single tertiary hospital between October 2016 and January 2019. Preoperative prostate volume was measured on MRI or ultrasonography. Follow-up was for a minimum of 18 months to enable longer term evaluation of complications.
Results
Of 304 HoLEPs performed, 104 were on patients with a prostate volume of ≥150cc(150-400cc). Mean age was 71 years, prostate volume 194cc, pre-operative Qmax 9.9ml/s, IPSS 21 points and median PSA of 9.86ng/ml. Laser and morcellation duration were 84 minutes and 28 minutes, respectively. Enucleated weight was 123g. Two required blood transfusion and three required a return to theatre, with no perioperative mortalities.
Follow-up showed mean Qmax of 32.0ml/s, IPSS 6.3 points and median PSA of 1.22ng/ml. 97.1% are catheter free. Significant stress urinary incontinence was present in 5.7% (1.9% requiring surgical intervention).
There were no significant difference in postoperative Qmax (32.3 vs 28.2 ml/s; p=0.06), IPSS (6.3 vs 7.2; p=0.41), stricture incidence (1% vs 3%; p=0.08) or catheter-free status (97.1% vs 97.5%; p=1.0) between the two cohorts ((≥150cc vs <150cc).
Conclusion
Our large series demonstrates that HoLEP is safe and effective in patients with massive prostates (≥150cc), with similar outcomes compared to patients with smaller prostates.
Introduction
There is limited evidence on perioperative and functional outcomes in patients with massive prostates undergoing HoLEP. In this study we assess outcomes following HoLEP in men with a prostate volume of ≥150cc and compared this to men with a prostate volume of ≤150cc.
Patients & Methods
We analysed our prospective database of consecutive patients undergoing HoLEP in a single tertiary hospital between October 2016 and January 2019. Preoperative prostate volume was measured on MRI or ultrasonography. Follow-up was for a minimum of 18 months to enable longer term evaluation of complications.
Results
Of 304 HoLEPs performed, 104 were on patients with a prostate volume of ≥150cc(150-400cc). Mean age was 71 years, prostate volume 194cc, pre-operative Qmax 9.9ml/s, IPSS 21 points and median PSA of 9.86ng/ml. Laser and morcellation duration were 84 minutes and 28 minutes, respectively. Enucleated weight was 123g. Two required blood transfusion and three required a return to theatre, with no perioperative mortalities.
Follow-up showed mean Qmax of 32.0ml/s, IPSS 6.3 points and median PSA of 1.22ng/ml. 97.1% are catheter free. Significant stress urinary incontinence was present in 5.7% (1.9% requiring surgical intervention).
There were no significant difference in postoperative Qmax (32.3 vs 28.2 ml/s; p=0.06), IPSS (6.3 vs 7.2; p=0.41), stricture incidence (1% vs 3%; p=0.08) or catheter-free status (97.1% vs 97.5%; p=1.0) between the two cohorts ((≥150cc vs <150cc).
Conclusion
Our large series demonstrates that HoLEP is safe and effective in patients with massive prostates (≥150cc), with similar outcomes compared to patients with smaller prostates.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}